Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Aromatic L-amino acid decarboxylase deficiency results in decreased neurotransmitter levels and severe motor dysfunction. Twenty-six patients without head control received bilateral intraputaminal infusions of a recombinant adeno-associated virus type 2 vector containing the human aromatic L-amino acid decarboxylase gene (eladocagene exuparvovec) and have completed 1-year evaluations. Rapid improvements in motor and cognitive function occurred within 12 months after gene therapy and were sustained during follow-up for >5 years. An increase in dopamine production was demonstrated by positron emission tomography and neurotransmitter analysis. Patient symptoms (mood, sweating, temperature, and oculogyric crises), patient growth, and patient caretaker quality of life improved. Although improvements were observed in all treated participants, younger age was associated with greater improvement. There were no treatment-associated brain injuries, and most adverse events were related to underlying disease. Post-surgery complications such as cerebrospinal fluid leakage were managed with standard of care. Most patients experienced mild to moderate dyskinesia that resolved in a few months. These observations suggest that eladocagene exuparvovec treatment for aromatic L-amino acid decarboxylase deficiency provides durable and meaningful benefits with a favorable safety profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A
Pasi, K. J., Rangarajan, S., Mitchell, N., Lester, W., Symington, E., Madan, B., Laffan, M., Russell, C. B., Li, M., Pierce, G. F., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1908490 · Cited by 448
Maguire, A. M., Russell, S., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., Marshall, K. A., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.06.017 · Cited by 409 · cited 1×
“In ocular gene therapy trials, substantial improvements in visual acuity forR4 years were noted in patients receiving AAV gene transfer for correction of Leber congenital amaurosis.(26) In gene therapy for hemophilia, the expressions of factor IX and factor VIII were observed for%3 years.”
Results from a phase I safety trial of hAADC gene therapy for Parkinson disease
Eberling, J. L., Jagust, W. J., Christine, C. W., Starr, P., Larson, P., Bankiewicz, K. S., & Aminoff, M. J. (2008) · Neurology · doi:10.1212/01.wnl.0000312381.29287.ff · Cited by 370
A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson’s disease
Muramatsu, S.-I., Fujimoto, K.-I., Kato, S., Mizukami, H., Asari, S., Ikeguchi, K., Kawakami, T., Urabe, M., Kume, A., Sato, T., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.135 · Cited by 344
Self-citationGene Therapy for Aromatic l -Amino Acid Decarboxylase Deficiency
Hwu, W.-L., Muramatsu, S.-I., Tseng, S.-H., Tzen, K.-Y., Lee, N.-C., Chien, Y.-H., Snyder, R. O., Byrne, B. J., Tai, C.-H., & Wu, R.-M. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003640 · Cited by 246 · cited 1×
“The safety of eladocagene exuparvovec treatment has been documented in previous studies.(16,17) This report adds to the existing body of evidence on the eladocagene exuparvovec safety by further assessing the short- and long-term (R5 years) tissue damage due to surgical intervention.”
Self-citationChien, Y.-H., Lee, N.-C., Tseng, S.-H., Tai, C.-H., Muramatsu, S.-I., Byrne, B. J., & Hwu, W.-L. (2017) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(17)30125-6 · Cited by 142
Self-citationGene therapy improves motor and mental function of aromatic l-amino acid decarboxylase deficiency
Kojima, K., Nakajima, T., Taga, N., Miyauchi, A., Kato, M., Matsumoto, A., Ikeda, T., Nakamura, K., Kubota, T., Mizukami, H., et al. (2019) · Brain · doi:10.1093/brain/awy331 · Cited by 139 · cited 1×
“The increase in PDMS-2 total scores after eladocagene exuparvovec treatment had a negative correlation with age (Table S1), indicating that younger patients exhibited faster and greater improvements in PDMS-2 scores after gene therapy, a finding similar to previous publications.(16,18) This is likely related to a grea…”
Self-citationEncouraging and Unsettling Findings in Long-Term Follow-up of AAV Gene Transfer
Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.007 · Cited by 18 · cited 2×
“In animal studies, hemophilia A dog models were shown to have persistent AAV8-mediated transgene expression for%10 years, although vector genome integration in the hepatocytes was questioned.(23,24) Persistent expression of dopamine-synthesizing enzymes, including AADC, has been shown 15 years after gene transfer in a…”
Cited by
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis
Shen, W., Liu, S., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1001263 · Cited by 173
“Unknown status suggests that study has passed its completion date and status has not been verified in more than two years. frontiersin.org Luxturna (32), and Upstaza (33) and one conditional approval Roctavian (34) in the USA and/or EU.”
AAV vectors applied to the treatment of CNS disorders: Clinical status and challenges
Kang, L., Jin, S., Wang, J., Lv, Z., Xin, C., Tan, C., Zhao, M., Wang, L., & Liu, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.067 · Cited by 131
An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species
Luo, S., Jiang, H., Li, Q., Qin, Y., Yang, S., Li, J., Xu, L., Gou, Y., Zhang, Y., Liu, F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48221-4 · Cited by 39
Metadata
- Authors
- Tai, C.-H., Lee, N.-C., Chien, Y.-H., Byrne, B. J., Muramatsu, S.-I., Tseng, S.-H., & Hwu, W.-L.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2022-02
- Volume
- 30
- Issue
- 2
- Pages
- 509-518
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W3214359432
- Cited by
- 162
- References
- 8
- FWCI
- 11.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency. https://app.cochat.ai/papers/10.1016/j.ymthe.2021.11.005
- The paper
- Tai, C.-H., Lee, N.-C., Chien, Y.-H., Byrne, B. J., Muramatsu, S.-I., Tseng, S.-H., & Hwu, W.-L. (2022). Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2021.11.005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.